Heron Therapeutics (NASDAQ:HRTX) reported fourth-quarter and full-year 2025 results while outlining plans to increase ...
CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...
Heron Therapeutics (HRTX) reported robust financial results for Q4 2025, highlighted by significant growth in its acute care portfolio. The company’s net revenues for the full year reached $154.9 ...
Image source: The Motley Fool. Heron Therapeutics (NASDAQ:HRTX) delivered operational and financial milestones, including full-year adjusted EBITDA above guidance and net product revenue gains led by ...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.
Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.01772, expectations were $-0.03. Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q4 2025 ...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2025 Earnings Call Transcript November 4, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results